» Articles » PMID: 35785878

The Adequacy of Current Diagnostic Criteria for Making a Diagnosis of ABPA

Overview
Journal Tuberk Toraks
Specialty Pulmonary Medicine
Date 2022 Jul 5
PMID 35785878
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Currently, there are four different diagnostic criteria systems for allergic bronchopulmonary aspergillosis (ABPA): The Rosenberg-Patterson, Seropositive ABPA (ABPA-S), Central Bronchiectasis and ABPA (ABPA-CB), and the International Society for Human and Animal Mycology (ISHAM) ABPA study group criteria. This study aims to retrospectively compare these four diagnostic criteria in ABPA patients.

Materials And Methods: Patients who were followed up with the diagnosis of ABPA were retrospectively re-evaluated using these four diagnostic criteria, and the superiority of these criteria to each other was determined.

Result: A total of 10 ABPA patients were included in the study. Seven patients were diagnosed according to ISHAM ABPA study group diagnostic criteria and six patients according to the Rosenberg-Patterson diagnostic criteria. None of the patients fulfilled the criteria when evaluated individually with ABPA-S and ABPA-CB. Of patients diagnosed by ISHAM, five had a total IgE level above 1000 IU/mL and two had below 1000 IU/mL.

Conclusions: We demonstrated that the diagnostic criteria developed by the ISHAM ABPA study group were superior to the others in diagnosing ABPA in cases with a total IgE level above 1000 IU/mL. However, all these criteria seem to be sufficient to diagnose ABPA in patients with a total IgE below 1000 IU/mL. We believe the necessity to demonstrate presence of Aspergillus fumigatus precipitating antibodies or specific IgG positivity should be questioned particularly in patients with radiologic findings compatible with ABPA and a total IgE level below 1000 IU/mL.

Citing Articles

Clinical significance of very high IgE levels (≥1000 IU/mL): Population-based study of 118,211 adults.

Nemet S, Elbirt D, Cohen R, Mahlab-Guri K, Bezalel-Rosenberg S, Asher I J Allergy Clin Immunol Glob. 2025; 4(2):100403.

PMID: 39931077 PMC: 11808720. DOI: 10.1016/j.jacig.2025.100403.


Aspergillus sensitisation detection using point-of-care lateral flow assay in moderate to severe asthma.

Wang R, Eades C, Palmer M, Platt G, Fowler S, Kosmidis C Med Mycol. 2023; 61(8).

PMID: 37491704 PMC: 10407838. DOI: 10.1093/mmy/myad076.